Search

Displaying results 2131 - 2140 of 7186 in total
  1. Drug

    4-Hydroxytestosterone

    go.drugbank.com/drugs/DB01485
    IllicitInvestigational

    It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency. … [A14385] Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in

  2. Drug

    Modified vaccinia ankara

    go.drugbank.com/drugs/DB15483
    ApprovedInvestigational

    Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus.

  3. Drug

    Pimozide

    go.drugbank.com/drugs/DB01100
    Approved

    (From AMA Drug Evaluations Annual, 1994, p403) … A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome.

  4. Drug

    Technetium Tc-99m tetrofosmin

    go.drugbank.com/drugs/DB09160
    Approved

    The radioisotope, technetium-99m, is chelated by two 1,2-bis[di-(2-ethoxyethyl)phosphino]ethane ligands which belong to the group of diphosphines and which are referred to as tetrofosmin. … [A31592] Technetium Tc-99m tetrofosmin was developed by GE Healthcare and FDA approved on February 9, 1996.

    Synonyms: Tc-99m tetrofosmin, Technetium Tc 99m tetrofosmin
  5. Drug

    Bronopol

    go.drugbank.com/drugs/DB13960
    Approved

    Compared to other aliphatic halogen-nitro compounds, bronopol is more stable to hydrolysis in aqueous media under normal conditions [A32792].

  6. Drug

    Isosorbide mononitrate

    go.drugbank.com/drugs/DB01020
    ApprovedInvestigational

    It is an anti-anginal agent that works by relaxing the smooth muscles of both arteries and veins, but but predominantly veins to reduce cardiac preload. … orally-administered isosorbide mononitrate is not rapid enough to offset an acute anginal episode.

  7. Drug

    Selpercatinib

    go.drugbank.com/drugs/DB15685
    ApprovedInvestigational

    It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc.[L13604] Selpercatinib is also approved by the European Commission.

  8. Drug

    Capmatinib

    go.drugbank.com/drugs/DB11791
    ApprovedInvestigational

    [A199122] Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways … a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.

  9. Drug

    Tetrofosmin

    go.drugbank.com/drugs/DB11180
    Approved

    Tetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds. … Tetrofosmin is used in conjunction with technetium Tc-99m as a radiopharmaceutical.[A7788]

  10. Drug

    Tapentadol

    go.drugbank.com/drugs/DB06204
    ApprovedInvestigational

    [A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome